AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03399903
Drug: Pentasa vs Align
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We will examine the safety and possible effectiveness of Pentasa® and Align in reducing markers of immune activation believed to be important reflectors of risk for cardiovascular disease and ongoing immune damage in people with chronic treated HIV-1 infection.
Trial: NCT00236171
Drug: Protopic, Advantan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00689624
Drug: Leukovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukovorin will be administered at a dose of 200mg/m2 as a 2-hour IV infusion on days 2 and 3
Trial: NCT01417052
Drug: 50 mg LX3305 QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg LX3305 once daily in capsule form
Trial: NCT01417052
Drug: 100 mg LX3305 QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg LX3305 once daily in capsule form
Trial: NCT01417052
Drug: 150 mg LX3305 QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg LX3305 once daily in capsule form
Trial: NCT01417052
Drug: 200 mg LX3305 QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg LX3305 once daily in capsule form
Trial: NCT01315041
Drug: Inert alcoholic solution
RxNorm normalized name: inert ingredients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 drops, PO, 3 times a day, during 16 weeks
Trial: NCT01417052
Drug: 250 mg LX3305 QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg LX3305 once daily in capsule form
Trial: NCT01417052
Drug: 300 mg LX3305 QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg LX3305 once daily in capsule form
Trial: NCT01417052
Drug: 400 mg LX3305 QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg LX3305 once daily in capsule form
Trial: NCT01417052
Drug: 250 mg LX3305 BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg LX3305 twice daily in capsule form
Trial: NCT01417052
Drug: 500 mg LX3305 QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg LX3305 once daily in capsule form
Trial: NCT01417052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo dosing in capsule form
Trial: NCT03617861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected once over one minute
Trial: NCT02470858
Drug: LDV/SOF+ASV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed-dose combination (FDC) tablet; administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
Trial: NCT01087580
Drug: Radiation Therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week.~GROUPS 2 Bone metastasis (bone scan index \< 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions.~GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week.
Trial: NCT03503825
Drug: [Tc-99m]-RPI-T-087 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous injection of \[Tc-99m\]-RPI-T-087 followed by SPECT/CT imaging of the knee (all subjects) and whole body planar imaging (Healthy volunteers only)
Trial: NCT01683162
Drug: Lipofundin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the lipid of all-in-one, 0.5-3.5g/kg.d
Trial: NCT04533243
Drug: 2.5ug/h transdermal fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5ug/h transdermal fentanyl administers for opioid-naive patients with moderate cancer pain very 3 days
Trial: NCT03153267
Drug: Doxycycline 100 MG Oral Tablet bid, 7 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive doxycycline for 7 days.
Trial: NCT03153267
Drug: Controls without a history of lyme disease.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention.
Trial: NCT04076423
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIC / FTC / TAF
Trial: NCT01570569
Drug: Cocktail
RxNorm normalized name: Cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A : Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.~Group B : Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
Trial: NCT01570569
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
Trial: NCT04580563
Drug: OctaplasLG®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient receive 12 ml/kg of OctaplasLG® at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
Trial: NCT04511195
Drug: Diclofenac Sodium Gel
RxNorm normalized name: diclofenac sodium Topical Gel
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each patient will be treated topically with a gel containing 2% diclofenac three times a day for 4 weeks.
Trial: NCT00882050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Placebo of NSS infused at same rate as drug comparator. Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA).
Trial: NCT00421824
Drug: Oxaliplatin, capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXA 130 D1 + Capecitabine 2000 / day D1-D14 for 4 cycles. After 10 weeks of rest, XELOX-RT regimen x 5 weeks followed by surgery
Trial: NCT00421824
Drug: Oxaliplatin, capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOX-RT x 5 weeks followed by surgery and 4 cycles of adjuvant XELOX with the same scheme as arm A.
Trial: NCT01131884
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is an inactive pill that will look similar to the active drug. You will not know whether you are receiving active drug or placebo.
Trial: NCT02214914
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03117894
Drug: Paracetamol 1,5 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered preoperatively to prevent pain postoperatively.
Trial: NCT03117894
Drug: Arcoxia, 120 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered preoperatively to prevent pain postoperatively.
Trial: NCT02935582
Drug: Other topical
RxNorm normalized name: Other topical products for joint and muscular pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment according to local practise
Trial: NCT00854919
Drug: atypical antipsychotic drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day) was added on ongoing SSRI(Paroxetine, Fluvoxamine).
Trial: NCT04580563
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient receive 12 ml/kg of placebo (0.9% NaCl) at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.
Trial: NCT00960349
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally at a dose of 1000mg/m2 twice daily for 2 weeks followed by a 1-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
Trial: NCT00193102
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine
Trial: NCT01739972
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine in a capsule form, once daily, with appropriate dosage to keep TSH in the normal range.
Trial: NCT01739972
Drug: Desiccated thyroid extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armour thyroid in a capsule form, once daily, with appropriate dosage to keep TSH in normal range.
Trial: NCT02322450
Drug: QGC001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02322450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01733485
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/8 h for 5 days
Trial: NCT01827878
Drug: Lisinopril and Hydrochlorothiazide Tablets (20+25) mg
RxNorm normalized name: lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
Trial: NCT01433523
Drug: ALK HDM AIT Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lyophilisate, Placebo, to be administered sublingually once daily
Trial: NCT03733561
Drug: LY03003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection)
Trial: NCT03733561
Drug: Neupro 4Mg/24Hr Transdermal Patch
RxNorm normalized name: Neupro 4mg/24hr Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neupro patch
Trial: NCT01617772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identically looking placebo
Trial: NCT04045821
Drug: AMD3100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this arm will have AMD3100 administered per the standard dosing regimen of 0.24 mg/kg actual body weight subcutaneous x1 dose
Trial: NCT04045821
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this arm will have a placebo of normal saline administered subcutaneously x1 dose
Trial: NCT02496767
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00170222
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03998163
Drug: CR845 0.5 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV CR845 0.5 mcg/kg administered three times/week
Trial: NCT01752153
Drug: Desferrioxamine, Legalon® (Silymarin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy)
Trial: NCT01752153
Drug: Silymarin (Legalon)
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04305496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match 400 mg BD (2 tablets of placebo to match 200 mg taken twice daily = placebo to match total daily dose of 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
Trial: NCT03191097
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, capsules daily for 5 days.
Trial: NCT02824536
Drug: 3BNC117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Infusion of 3BNC117
Trial: NCT02824536
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Infusion of Sterile Saline (NaCl 0.9%)
Trial: NCT03181503
Drug: CD14152 Dose A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
Trial: NCT03181503
Drug: CD14152 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
Trial: NCT03616444
Drug: Shenbai Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the first year, the trial granules will be started after enrollment for 3 months; In the second year, the trial granules will be started in the first 3 months; Each participant should have completed 6 months of trial granules.
Trial: NCT00673725
Drug: Locobase® REPAIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: emollient
Trial: NCT04658823
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Softgel capsule containing soybean oil; 1 capsule twice daily
Trial: NCT03879408
Drug: 440 mg naproxen sodium with 1000 mg acetaminophen
RxNorm normalized name: acetaminophen / naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets
Trial: NCT03879408
Drug: 220 mg naproxen sodium with 650 mg acetaminophen
RxNorm normalized name: naproxen sodium 220 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet
Trial: NCT03879408
Drug: 10 mg hydrocodone + 650 mg acetaminophen
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg hydrocodone with 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets
Trial: NCT03879408
Drug: 440 mg naproxen sodium
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets
Trial: NCT03879408
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of four placebo tablets
Trial: NCT01490125
Drug: Placebo to QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0 mg hard non-gelatin capsule, inhalation/ blister once a day via SDDPI
Trial: NCT00598234
Drug: Celecoxib (Celebrex)
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study group received 400mg oral celecoxib about 1 hr prior to surgery, and 200mg every 12 hrs, along with PCA morphine, over the first five post-operative days. The control group received placebo, along with PCA morphine over the same postoperative period. All patients received Acetaminophen 500mg qid for pain control.
Trial: NCT01676792
Drug: SR-T100 gel with 2.3% of SM in Solanum undatum plant extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self administered topical SR-T100 gel on lesion(s) including its peripheral normal skin approximately 1cm around the lesion with the amount of 0.02 g/cm squared with occlusive dressing once daily. Patients who is unable to tolerate with occlusive dressing is instructed 3 times daily in the morning, afternoon \& before bed time. Medication should be reapply after bathing or cleaning.
Trial: NCT01779596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03235375
Drug: MEDI0382
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI0382 administered subcutaneously
Trial: NCT02581124
Drug: JTZ-951
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01078519
Drug: Combined epidural and spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obstetrics patients will relieve spinal anesthesia with local anesthesics and opioids associated with epidural anesthesia with local anesthetics in low concentrations with opioids
Trial: NCT03150498
Drug: BTD-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTD-001 in fed vs fasted state
Trial: NCT04189263
Drug: standard of care aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard of care aromatase inhibitors
Trial: NCT00715182
Drug: TKI258
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00213759
Drug: dextrose 5%
RxNorm normalized name: Dextrose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo (dextrose 5% ) will be injected by intravenous way with the amount of 0.66 ml/kg during 3 days consecutive. The infusion will last from 20 to 40 minutes.
Trial: NCT01303744
Drug: CHF 5074 2x
RxNorm normalized name: Worm Protector 2X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 8 weeks
Trial: NCT01303744
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet, once a day in the morning for 12 weeks
Trial: NCT01754389
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00997750
Drug: Lornoxicam
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lornoxicam 8mg/day and 12mg/day for 15 days
Trial: NCT01023841
Drug: Vehicle Sterile Solution
RxNorm normalized name: Steril-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
Trial: NCT03080116
Drug: ARN-509
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240mg/day (4x60mg tablets, Oral administration: OS)
Trial: NCT00070018
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m\^2
Trial: NCT00070018
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m\^2
Trial: NCT02961062
Drug: SAF312
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02961062
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03014713
Drug: Flubiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flubiprofen 0.5mg/kg/h intravenous administration during the first two days after surgery.
Trial: NCT03484221
Drug: FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRINOTECAN 150 mg/m\^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m\^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m\^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m\^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
Trial: NCT03484221
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OXALIPLATIN 130 mg/m\^2 IV over 2-h, day 1 Capecitabine 1000 mg/m\^2 twice daily days 1-14 every 3 weeks for 4 cycles.
Trial: NCT00829816
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03688958
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selected patients with early breast cancer (stage II) non-pretreated received colored water solution (placebo) within the time before the hospital assigned them to her surgery (7 to 35 days).
Trial: NCT02271906
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
Trial: NCT01953835
Drug: GSK2586184 standard formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2586184 standard formulation is a white film coated round biconvex 200 mg oral tablet. For cohort A, it is to be administered at 400 mg (200 mg x 2 tablets) twice daily from Day 6 to Day 14. For cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose after standard breakfast either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day wash out period.
Trial: NCT01953835
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 mg oral tablet is peach-coloured, oval-shaped tablets. It is to be administered orally as a single dose of 10 mg tablet on the mornings of Day 1 and Day 10.
Trial: NCT01953835
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
Trial: NCT01953835
Drug: GSK2586184 new formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
Trial: NCT04314206
Drug: Placebo for VNRX-5024
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: one dose~Part 2:~Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours \[q12h\] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours \[q8h\] dosing for 9 days with a single morning dose on Day 10)